Combination of ADT with the androgen receptor (AR)–signaling inhibitors, such as abiraterone,5,6 enzalutamide,7 apalutamide,8 and darolutamide,9,10 provides additional clinical benefits for males with advanced PC both in the castrate sensitive M1 and castrate resistance M0 disease states. This evidence concerns the gene AR and pachyonychia congenita.